Please check your internet connection and try again.
## IV Hydrocortisone for Acute Asthma
### Overview
Intravenous hydrocortisone is a systemic corticosteroid used as an adjunct therapy in moderate to severe acute asthma exacerbations, particularly when patients do not respond adequately to initial bronchodilator therapy or are unable to take oral medications. It works by reducing airway inflammation, decreasing mucus production, and potentiating the effects of beta-agonists.
### Primary Indications
Adjunctive treatment of moderate to severe acute asthma exacerbations in patients who do not respond adequately to initial bronchodilator therapy or are unable to take oral medications.
### Adult Dosing
* **Initial Dose:** 100 mg IV every 6 to 8 hours.
* **Alternative (Continuous Infusion):** 200 mg IV continuous infusion over 24 hours.
* **Duration:** Treatment duration is typically short, often 24 to 72 hours, or until clinical improvement allows for transition to oral corticosteroids.
### Pediatric Dosing
* **Children:** 1 to 2 mg/kg per dose IV every 6 hours.
* **Maximum Dose:** Generally not to exceed 100 mg per dose. Some protocols may use higher doses, consult local guidelines.
### Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is routinely recommended.
* **Hepatic Impairment:** No specific dose adjustment is routinely recommended, but caution may be warranted due to potential for altered metabolism.
### Contraindications
* Known hypersensitivity to hydrocortisone or other components of the formulation.
* Systemic fungal infections.
* Use with caution in patients with active tuberculosis, peptic ulcer disease, or recent gastrointestinal anastomosis.
### Adverse Effects
Common adverse effects are generally related to short-term, high-dose use and can include hyperglycemia, insomnia, mood changes, increased appetite, and fluid retention. Long-term or repeated use can lead to more serious effects such as immunosuppression, adrenal suppression, osteoporosis, Cushingoid changes, and psychiatric disturbances.
### Key Drug Interactions
* **Potent CYP3A4 Inhibitors (e.g., ketoconazole, ritonavir):** May increase hydrocortisone levels.
* **CYP3A4 Inducers (e.g., rifampin, phenytoin, carbamazepine):** May decrease hydrocortisone levels.
* **Diuretics (non-potassium sparing):** Increased risk of hypokalemia.
* **Vaccines:** Reduced immune response to live or inactivated vaccines.
### Monitoring
* **Clinical Response:** Monitor respiratory rate, work of breathing, oxygen saturation, and peak expiratory flow rates.
* **Electrolytes:** Especially potassium, particularly with concurrent diuretic use.
* **Blood Glucose:** Monitor for hyperglycemia, especially in patients with diabetes or those at risk.
* **Signs of Infection:** Corticosteroids can mask infections.
### Clinical Pearls
* IV hydrocortisone is generally considered less potent and has a shorter duration of action compared to other IV corticosteroids like dexamethasone. However, it is often readily available.
* Early administration is crucial. Optimal benefit is seen when given within the first hour of presentation.
* Transition to oral corticosteroids as soon as the patient can tolerate oral intake and shows clinical improvement.
* Ensure adequate hydration and electrolyte balance.
* Consider the potential for adrenal suppression if the patient has been on chronic corticosteroids or if prolonged IV therapy is anticipated.
***
*This information is intended for healthcare professionals. Always verify the most current prescribing information and local institutional protocols before administering any medication.*
